Madrigal Pharmaceuticals Future Growth
Future criteria checks 5/6
Madrigal Pharmaceuticals is forecast to grow earnings and revenue by 73.1% and 54.4% per annum respectively. EPS is expected to grow by 72.5% per annum. Return on equity is forecast to be -87.9% in 3 years.
Key information
73.1%
Earnings growth rate
72.5%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 54.4% |
| Future return on equity | -87.9% |
| Analyst coverage | Good |
| Last updated | 20 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,002 | 131 | 99 | 382 | 13 |
| 12/31/2025 | 576 | -286 | -226 | -195 | 16 |
| 12/31/2024 | 169 | -501 | -530 | -428 | 13 |
| 9/30/2024 | 77 | -519 | -438 | -431 | N/A |
| 6/30/2024 | 15 | -510 | -456 | -449 | N/A |
| 3/31/2024 | N/A | -444 | -391 | -389 | N/A |
| 12/31/2023 | N/A | -374 | -326 | -324 | N/A |
| 9/30/2023 | N/A | -347 | -303 | -303 | N/A |
| 6/30/2023 | N/A | -330 | -277 | -277 | N/A |
| 3/31/2023 | N/A | -315 | -259 | -259 | N/A |
| 12/31/2022 | N/A | -295 | -225 | -225 | N/A |
| 9/30/2022 | N/A | -274 | -215 | -214 | N/A |
| 6/30/2022 | N/A | -256 | -201 | -201 | N/A |
| 3/31/2022 | N/A | -247 | -191 | -190 | N/A |
| 12/31/2021 | N/A | -242 | -184 | -184 | N/A |
| 9/30/2021 | N/A | -236 | -191 | -191 | N/A |
| 6/30/2021 | N/A | -231 | -193 | -193 | N/A |
| 3/31/2021 | N/A | -219 | -171 | -170 | N/A |
| 12/31/2020 | N/A | -202 | -158 | -158 | N/A |
| 9/30/2020 | N/A | -171 | -115 | -115 | N/A |
| 6/30/2020 | N/A | -134 | -79 | -78 | N/A |
| 3/31/2020 | N/A | -105 | -66 | -66 | N/A |
| 12/31/2019 | N/A | -84 | -42 | -42 | N/A |
| 9/30/2019 | N/A | -68 | -36 | -36 | N/A |
| 6/30/2019 | N/A | -55 | -30 | -30 | N/A |
| 3/31/2019 | N/A | -42 | -23 | -23 | N/A |
| 12/31/2018 | N/A | -33 | -26 | -26 | N/A |
| 9/30/2018 | N/A | -30 | -25 | -25 | N/A |
| 6/30/2018 | N/A | -30 | N/A | -25 | N/A |
| 3/31/2018 | N/A | -32 | N/A | -27 | N/A |
| 12/31/2017 | N/A | -31 | N/A | -22 | N/A |
| 9/30/2017 | N/A | -30 | N/A | -22 | N/A |
| 6/30/2017 | N/A | -36 | N/A | -26 | N/A |
| 3/31/2017 | N/A | -31 | N/A | -21 | N/A |
| 12/31/2016 | N/A | -26 | N/A | -18 | N/A |
| 9/30/2016 | N/A | -21 | N/A | -13 | N/A |
| 6/30/2016 | N/A | -8 | N/A | -5 | N/A |
| 3/31/2016 | N/A | -7 | N/A | -3 | N/A |
| 12/31/2015 | N/A | -7 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: YDO1 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: YDO1 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: YDO1 is expected to become profitable in the next 3 years.
Revenue vs Market: YDO1's revenue (54.4% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: YDO1's revenue (54.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: YDO1 is forecast to be unprofitable in 3 years.